Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

unprecedented number of orphan receptors, and our addiction and high-risk bleeding programs advanced toward the clinic. Following the close of the quarter, we added over $17 million to our balance sheet, positioning Omeros to execute on a series of value-driving milestones during the remainder of 2013 and well into 2014."

Third Quarter and Recent Highlights

  • Reported U.S. and European regulators had accepted Omeros' OMS302 marketing applications for review. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery® product designed to maintain intraoperative mydriasis, prevent miosis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Omeros is preparing for a planned commercial launch of OMS302 in the second half of 2014.
  • Announced that Omeros entered into a settlement agreement with Carolina Casualty Insurance Company, or, CCIC, dated October 2, 2013, related to CCIC's defense of, and coverage obligations owed to, Omeros and its chief executive officer and chairman, Dr. Demopulos, in previously settled litigation with Omeros' former chief financial officer. The settlement included a release of each party's respective claims in the insurance coverage lawsuit and payment by CCIC of $12.5 million to Omeros, which was received on October 24, 2013.
  • Reported positive clinical data from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.  Omeros subsequently started a Phase 2 trial evaluating the drug in patients with schizophrenia and plans to start a Phase 2 trial in Huntington's disease in early 2014. OMS824 has received orphan drug designation from the
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
    (Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
    (Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
    (Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
    Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
    ... N.C., Dec. 8, 2010 Pharmaceutical Institute, ... pharmaceutical and biotech industry and a subsidiary of Campbell ... Hospital Marketplace e-course series.  It ... and Institutional IT Systems ...
    ... 8, 2010 Reportlinker.com announces that a new ... Merck KGaA: PharmaVitae Profile ... IntroductionThis analysis examines the historical and forecast ... sector. The profile encompasses global company strategy, portfolio ...
    ... 8, 2010 Aquatic Energy LLC announced today that ... Zulandi, have joined its Board of Directors.  "Our new ... experience to our company," stated David Johnston, CEO of ... time, as the company moves from proof-of-concept demonstration facilities ...
    Cached Biology Technology:Hospital Marketplace E-Course Suite Adds Insight on Quality and Information Systems 2Reportlinker Adds Merck KGaA: PharmaVitae Profile 2Senior Energy Executives Join Aquatic Energy Board 2Senior Energy Executives Join Aquatic Energy Board 3
    (Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today ... the University of Massachusetts Amherst School of Public ... three-year, $700,000 Science to Achieve Results (STAR) grant ... by Native subsistence hunters in subarctic North America ... exposure and to provide culturally-relevant recommendations for mitigation. ...
    (Date:7/23/2014)... fable about the crow and the pitcher, a thirsty bird ... to drink from it, he finds the water level out ... pitcher, the bird drops pebbles into it one at ... him to drink his fill. , Highlighting the value of ... more effective than brute force. It also characterizes crows as ...
    (Date:7/23/2014)... Defense recently awarded the STEMPREP Project at Southern ... its goal of increasing the number of minorities ... middle school students for the two-summer classroom phase ... students with summer opportunities at research labs. , ... School of Education and Human Development, boasts an ...
    Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
    ... are common, but few studies of lung nodule identification ... Researchers from Kaiser Permanente Southern California identified 7,112 patients ... information within the electronic medical record. Their ... International Association for the Study of Lung Cancer,s (IASLC) ...
    ... Your genes determine much about you, but environment can ... with consequences that can last a lifetime. In a ... ), researchers have for the first time shown that the ... the chemical modifications to DNA we are born with, that ...
    ... some cases of the progressive fatal neurological disease amyotrophic ... disease. Shedding light on how ALS destroys the cells ... in this gene affect the structure and growth of ... cells responsible for controlling muscles. People with ALS experience ...
    Cached Biology News:Differences between human twins at birth highlight importance of intrauterine environment 2New gene mutations linked to ALS and nerve cell growth dysfunction 2New gene mutations linked to ALS and nerve cell growth dysfunction 3
    ... enterprise microarray informatics platform for microarray data storage, ... and use it forever without paying ongoing license ... Acuity has all the analysis tools you need ... quality control statistics and normalization, all the way ...
    ... industry standard microarray image analysis software because ... analysis tools, visualizations, automation capabilities, performance and ... with every GenePix scanner, and it also ... all types of arrays. A wide range ...
    A univariate (peak height or area) quantitative multi-component analysis package....
    ... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
    Biology Products: